Stay updated on Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial page.

Latest updates to the Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision entry, v3.4.2, was added to the record history, and the government funding notice banner was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check20 days agoChange DetectedThe history page now includes a government funding notice and a new revision tag (v3.4.1) while the prior revision (v3.4.0) is removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check28 days agoChange DetectedUI updates include a 'Show glossary' option, visible color-coded highlights for additions and deletions, and a new revision tag 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check42 days agoChange DetectedNew revision v3.3.4 was added to the study record history, and revision v3.3.3 was removed, reflecting a minor update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange Detected- The changes consist of a new revision entry (Revision: v3.3.3) and removal of the HHS Vulnerability Disclosure and Revision: v3.3.2 from the page footer; these updates do not alter core trial data, eligibility, locations, or other substantive content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check85 days agoChange DetectedThe History page now shows a new revision entry (v3.3.2) added and the previous revision (v3.3.1) removed; no changes to the study data, status, or visible content are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial page.